$68.17 +0.42 (%) Novartis Shs Sponsored American Deposit Receipt Repr 1 Sh - New York Stock Exchange, Inc.

Dec. 2, 2016 | 04:00 PM

Headlines

  1. Quotes

  2. Charts

  3. Analysis

  4. Options

  5. Historical



Partner Headlines

  1. Lung Disease Stocks Advance After Actelion Approached By J&J

    TalkMarkets | Nov. 25, 2016 | 17:04PM EST
  2. Calithera In Focus, Part 2 - Upcoming Catalysts In TNBC And RCC

    TalkMarkets | Nov. 23, 2016 | 11:45AM EST
  3. Batten Down The Bonds

    TalkMarkets | Nov. 14, 2016 | 23:38PM EST
  4. Markets In Turmoil: Global Bond Bloodbath, Currency Rout Accelerates As Stocks Erase Early Gains

    TalkMarkets | Nov. 14, 2016 | 06:53AM EST
  5. Pharmaceutical Stocks Surge After Republican Victory

    TalkMarkets | Nov. 9, 2016 | 12:48PM EST
  6. IPO Preview: Ra Pharmaceuticals

    TalkMarkets | Oct. 26, 2016 | 01:02AM EST
  7. Apple Bites - Financial Review

    TalkMarkets | Oct. 25, 2016 | 23:03PM EST
  8. Novartis Tops Q3 Earnings, Misses Sales Estimates

    TalkMarkets | Oct. 25, 2016 | 12:47PM EST
  9. Phase 2b Data Continues To Impress From HedgePath Pharma

    TalkMarkets | Oct. 21, 2016 | 04:18AM EST
  10. 7 Drug Stocks To Consider As Biosimilars Pick Up Pace

    TalkMarkets | Oct. 20, 2016 | 13:53PM EST
  11. Bristol-Myers Falls As Merck Upstages With New Lung Cancer Data

    TalkMarkets | Oct. 10, 2016 | 18:35PM EST
  12. Week In Review: Teva Pays $160 Million For US/Canada Rights To Celltrion Biosimilars

    TalkMarkets | Oct. 8, 2016 | 13:30PM EST
  13. 10 Stocks John Rogers Keeps Buying

    GuruFocus | Sep. 27, 2016 | 16:59PM EST
  14. Kite Pharma Soars As Cancer Drug Trial Supportive Of FDA Approval

    IBD | Sep. 27, 2016 | 15:20PM EST
  15. Kite Pharma Jumps After CAR-T Cancer Drug Success

    TalkMarkets | Sep. 26, 2016 | 22:04PM EST
  16. The Internet Of Medical Things: 6 Stocks In Focus

    TalkMarkets | Sep. 26, 2016 | 12:20PM EST
  17. Apple, Facebook, Alphabet, Amazon, Ford, McDonald's Headline Busy Week

    Investors Business Daily | Jul. 29, 2016 | 11:13AM EST
  18. Week In Review: Stock Breakouts, Netflix Subs Snub, Tesla's Plan, M&A News

    Investors Business Daily | Jul. 22, 2016 | 11:25AM EST
  19. Lilly, J&J, Novo Battle For Diabetes Market Heats Up; FDA Rulings Loom

    Investors Business Daily | Jul. 22, 2016 | 09:44AM EST
  20. Roche Holdings Definitely Not a Lumbering Giant

    GuruFocus | Jul. 11, 2016 | 12:24PM EST
  21. Valeant's Share Price Continues to Decline

    GuruFocus | Feb. 5, 2016 | 15:10PM EST
  22. Earnings Recap For January 27

    Benzinga | Jan. 27, 2016 | 17:17PM EST
  23. 10 Fund Managers Are Totally Wrong on GlaxoSmithKline

    GuruFocus | Jan. 26, 2016 | 14:59PM EST
  24. Guru Stocks at 52-Week Lows

    GuruFocus | Jan. 26, 2016 | 12:26PM EST
  25. Juno Buyout Puts Single-Cell Sequencing In Spotlight

    IBD | Jan. 15, 2016 | 17:30PM EST
  26. Berkshire Hathaway, Wells Fargo, China Mobile, Novartis, Bank of America Reach 52-Week Lows

    GuruFocus | Jan. 11, 2016 | 13:36PM EST
  27. Novartis Announces Collaboration and Licensing Agreement with Surface Oncology

    Benzinga | Jan. 11, 2016 | 04:19AM EST
  28. Mylan, Momenta Team Up To Develop Biosimilar Drugs

    IBD | Jan. 8, 2016 | 15:34PM EST
  29. 3 Potential Blockbuster Drugs Launching in 2016

    IBD | Jan. 6, 2016 | 09:42AM EST
  30. Berkshire Hathaway, China Mobile, Novartis, Oracle, PetroChina Near 52-Week Lows

    GuruFocus | Jan. 4, 2016 | 12:52PM EST
  31. Big Biotech Amgen Facing Pivotal Year In 2016

    IBD | Dec. 17, 2015 | 17:08PM EST
  32. Novartis Announces New CTL019 Study Data Demonstrating Overall Response in Adults with Certain Types of Lymphoma at #ASH2015

    Benzinga | Dec. 6, 2015 | 08:43AM EST
  33. Novartis Announces Phase III Studies of Jakavi Show Disease Improvement in Patients with Myelofibrosis and Polycythemia Vera

    Benzinga | Dec. 5, 2015 | 10:18AM EST
  34. Weekend Watch: Yahoo's Fate, Blood Cancer Fighters

    IBD | Dec. 5, 2015 | 08:02AM EST
  35. Amgen Expands Work With Merck, Files Biosimilar In EU

    IBD | Dec. 4, 2015 | 13:46PM EST
  36. Blood-Cancer Drugs In Focus

    IBD | Dec. 2, 2015 | 18:47PM EST
  37. Blood-Cancer Fighters To Strut Their Stuff At ASH

    IBD | Dec. 2, 2015 | 08:02AM EST
  38. Sanofi Chipping Away At Biogen's MS Dominance

    IBD | Nov. 30, 2015 | 11:32AM EST
  39. Skin Disease Drug Costs Jump

    IBD | Nov. 25, 2015 | 18:34PM EST
  40. Biotechs Weaken, But These Names Have Bullish Charts

    IBD | Nov. 25, 2015 | 17:19PM EST
  41. Valeant, Glaxo, Novartis Skin Drug Prices Have Soared

    IBD | Nov. 25, 2015 | 17:01PM EST
  42. Novartis Announces EC Approvals for Cosentyx to Treat Patients with Ankylosing Spondylitis, Psoriatic Arthritis

    Benzinga | Nov. 23, 2015 | 04:12AM EST
  43. Goldman Sachs' Top 4 Smid-Cap Biotech Picks

    IBD | Nov. 18, 2015 | 15:36PM EST
  44. Novartis Presents New Two-year Data for Cosentyx Showing No Progression in Joint Damage in 84% of Psoriatic Arthritis Patients

    Benzinga | Nov. 7, 2015 | 20:03PM EST
  45. Celgene Reports Mixed Q3 As Cancer Rivals Rise

    IBD | Nov. 5, 2015 | 17:37PM EST
  46. Roche Touts New MS Drug As Legacy Players Hit Snags

    IBD | Nov. 3, 2015 | 08:02AM EST
  47. Guru Stocks at 52-Week Lows: NVS, WMT, IBM, AXP, CHU

    GuruFocus | Nov. 1, 2015 | 17:27PM EST
  48. AbbVie Beats Q3 Views, Offers Bullish 2020 Guidance

    IBD | Oct. 30, 2015 | 09:00AM EST
  49. Apple Upgraded, Alibaba PTs Hiked, Twitter PTs Cut

    IBD | Oct. 28, 2015 | 08:39AM EST
  50. Eli Lilly Q3 Earnings, Guidance Beat On Cost Control

    IBD | Oct. 22, 2015 | 11:36AM EST
Trading Center